Vera Therapeutics logo

Vera TherapeuticsNASDAQ: VERA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

14 May 2021

Next earnings report:

09 May 2025

Last dividends:

N/A

Next dividends:

N/A
$2.90 B
-9%vs. 3y high
85%vs. sector
-vs. 3y high
-vs. sector
-62%vs. 3y high
92%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 59 min ago
$45.75$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

VERA Latest News

Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet
zacks.com11 November 2024 Sentiment: POSITIVE

The consensus price target hints at a 27.3% upside potential for Vera Therapeutics (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Vera Therapeutics to Participate at Upcoming Investor Conferences
globenewswire.com08 November 2024 Sentiment: POSITIVE

BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.

Vera Therapeutics to Participate at Upcoming Investor Conferences
globenewswire.com08 November 2024 Sentiment: POSITIVE

BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
globenewswire.com29 October 2024 Sentiment: POSITIVE

BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 7,142,858 shares of its Class A common stock at a price to the public of $42.00 per share.

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
globenewswire.com28 October 2024 Sentiment: POSITIVE

BRISBANE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $300.0 million of shares of its Class A common stock. All of the shares are being offered by Vera.

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
globenewswire.com26 October 2024 Sentiment: POSITIVE

BRISBANE, Calif., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN) that show stabilized kidney function through 96 weeks of long-term follow-up. These data were presented in a late-breaking oral presentation at the American Society of Nephrology Kidney Week 2024 in San Diego, California, and simultaneously published in a manuscript in the Journal of the American Society of Nephrology.

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients
seekingalpha.com04 October 2024 Sentiment: POSITIVE

Vera Therapeutics, Inc. topline 36-week data from the phase 3 ORIGIN study, using Atacicept for the treatment of patients with IgA Nephropathy, expected Q2 of 2025. 96-week data from the phase 2 ORIGIN study, using Atacicept for the treatment of patients with IgA Nephropathy, expected at ASN Kidney week oral presentation October 23–27 2024. The global IgA Nephropathy market is expected to reach $41.24 billion by 2033.

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
globenewswire.com02 October 2024 Sentiment: POSITIVE

BRISBANE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced expansion of its development pipeline for its lead asset, atacicept. This program is expected to build on the positive data reported to date from the ongoing ORIGIN Phase 2b and 3 clinical program developing atacicept to treat patients with IgAN, by extending into a broader population of IgAN and other autoimmune kidney indications.

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
globenewswire.com11 June 2024 Sentiment: POSITIVE

BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches.

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
globenewswire.com28 May 2024 Sentiment: POSITIVE

BRISBANE, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to atacicept for the treatment of IgAN. The designation reflects the FDA's determination that, based on an assessment of data from the Phase 2b ORIGIN clinical trial of atacicept for IgAN, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with IgAN.

  • 1(current)

What type of business is Vera Therapeutics?

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

What sector is Vera Therapeutics in?

Vera Therapeutics is in the Healthcare sector

What industry is Vera Therapeutics in?

Vera Therapeutics is in the Biotechnology industry

What country is Vera Therapeutics from?

Vera Therapeutics is headquartered in United States

When did Vera Therapeutics go public?

Vera Therapeutics initial public offering (IPO) was on 14 May 2021

What is Vera Therapeutics website?

https://veratx.com

Is Vera Therapeutics in the S&P 500?

No, Vera Therapeutics is not included in the S&P 500 index

Is Vera Therapeutics in the NASDAQ 100?

No, Vera Therapeutics is not included in the NASDAQ 100 index

Is Vera Therapeutics in the Dow Jones?

No, Vera Therapeutics is not included in the Dow Jones index

When was Vera Therapeutics the previous earnings report?

No data

When does Vera Therapeutics earnings report?

The next expected earnings date for Vera Therapeutics is 09 May 2025